All Industries

Top Therapeutics Companies

203 Therapeutics companies, sorted by total funding raised.

MetacrineIPO

Metacrine is a biotech company developing innovative therapeutics for liver, gastrointestinal, an...

San Diego, United States11–50Biotech, Therapeutics
Series C·$123.0M·Jun 2018
Ouro Medicines

Biotechnology company dedicated to developing immune reset therapeutics for people living with ch...

USA, United States11–50Biotech, Immunology
Series A·$120.0M·Jan 2025
Shinobi Therapeutics

Develops immune-evasive iPSC-derived off-the-shelf cell therapies for cancer and autoimmune disea...

San Diego, United States11–50Biotech, Therapeutics
Grant·$119.0M·Aug 2024
GenEdit

GenEdit is revolutionizing gene therapy and gene editing with its nanoparticle delivery technology.

South San Francisco, United States51–200Biotech, Therapeutics
Series B·$118.5M·Feb 2026
Nkarta TherapeuticsIPO

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural ...

South San Francisco, United States51–200Biotech, Oncology
Series B·$114.0M·Sep 2019
Myricx Bio

Biotech company focused on cell and gene therapy development.

London, United Kingdom1–10Biotech, Therapeutics
Venture Unknown·$113.0M·Jul 2024
Dyno Therapeutics

Biotechnology company applying artificial intelligence to design novel AAV vectors for gene thera...

Cambridge, United States51–200Artificial Intelligence, Biotech
Series A·$109.0M·May 2021
Click Therapeutics

Digital therapeutics and behavioral health company using software as medicine.

New York, United States51–200Digital Health, Therapeutics
Series D·$102.0M·Apr 2026
Satellite Bio

Develops off-the-shelf liver cell therapies that deliver functional hepatocytes to restore liver ...

Cambridge, United States11–50Biotech, Life Sciences
Seed·$101.5M·Apr 2022
Catalyst BiosciencesAcquired

Biopharmaceutical company focused on drugs to treat CNS disorders by targeting neuronal nicotinic...

South San Francisco, United States11–50Biotech, Therapeutics
Corporate Round·$100.4M·Jan 2011
NightstarAcquired

Private biopharmaceutical company focused on the development of therapies for retinal dystrophies.

Oxford, United Kingdom51–200Biotech, Healthcare
Series C·$99.1M·Jun 2017
IconOVir Bio

Preclinical-stage biotech developing next-generation oncolytic virus therapies for solid tumors.

San Diego, United States11–50Biotech, Drug Discovery
Venture Unknown·$97.2M·Jun 2024
Orbis Medicines

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery.

Copenhagen, Denmark11–50Biotech, Drug Discovery
Series B·$93.0M·Jan 2025
Maxion Therapeutics

Biotech developing antibody-based KnotBody therapeutics targeting ion channels and GPCRs to treat...

Cambridge, United Kingdom11–50Life Sciences, Biotech
Series A·$88.0M·Mar 2025
Amicus TherapeuticsIPO

Oral pharmacological chaperone protein therapies to address diseases that result from protein mis...

Cranbury, United States501–1000Biotech, Drug Discovery
Venture Unknown·$86.0M·Jan 2006
Tempest TherapeuticsIPO

A clinical-stage oncology company advancing small molecules that combine both targeted and immune...

Brisbane, United States11–50Biotech, Drug Discovery
Private Equity·$85.0M·Apr 2022
Code Biotherapeutics

A next-generation gene therapy company pioneering the development of targeted non-viral gene ther...

Hatfield, United States11–50Biotech, Therapeutics
Series A·$85.0M·Jun 2022
Kala PharmaceuticalsIPO

Clinical-stage biopharma developing topical nanoparticle therapies for eye diseases, including tr...

Waltham, United StatesBiotech, Healthcare
Venture Unknown·$79.5M·Apr 2016
ARS PharmaceuticalsIPO

Develops and commercializes neffy, an FDA-approved needle-free epinephrine nasal spray for treati...

San Diego, United States51–200Healthcare, Therapeutics
Series D·$75.0M·Aug 2021
Georgiamune

Clinical-stage biotech developing immunotherapies that reprogram immune signaling to treat cancer...

Gaithersburg, United States11–50Life Sciences, Biotech
Series A·$75.0M·Aug 2023
Precision BioSciencesIPO

Clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS geno...

Durham, United States51–200Biotech, Gene Editing
Venture Unknown·$75.0M·Jun 2022
Spark TherapeuticsAcquired

Spark Therapeutics develops gene therapy treatments for debilitating genetic diseases; acquired b...

Philadelphia, United States201–500Biotech, Therapeutics
Series B·$72.8M·May 2014
Delphia Therapeutics

Biotech developing 'activation lethality' cancer therapeutics that overactivate oncogenes to sele...

Cambridge, United States11–50Biotech, Therapeutics
Series A·$67.0M·May 2024
Bionaut Labs

Develops microscale wireless micro-robots to deliver therapies and diagnostics to deep body locat...

Los Angeles, United States11–50Biotech, Medical Devices
Extension Round·$63.2M·Feb 2024
Shasqi

Biotech company using click chemistry to selectively activate cancer drugs at the tumor site, imp...

San Francisco, United States11–50Biotech, Healthcare
Series B·$60.5M·Nov 2021